Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Oral heparin completes phase I testing

May 10, 2001

Promising preclinical data reported for argatroban in rat ischemic stroke model

May 10, 2001

Inhibitors of factor Xa under development at Cor Therapeutics

May 8, 2001

Novel P2T receptor antagonists identified at AstraZeneca as potential antithrombotics

May 8, 2001

Antithrombotic activity of agkistin related to platelet gpIb antagonism

May 8, 2001

Reviparin compared to heparin in deep vein thrombosis

May 4, 2001

Protein enters preclinical development for acute thrombosis at Myriad Genetics

May 3, 2001

Antithrombotic pentasaccharide assigned fast track review by FDA

May 3, 2001

3-D's new serine protease inhibitors and their use disclosed in recent patent

May 2, 2001

Potent anticoagulant activity of ART-123 associated with reduced effects on hemostasis

April 24, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...